AR069146A1 - Derivados de pirimidina, composicion farmaceutica que los comprende y el uso de esta para el tratamiento de enfermedades relacionadas con la activacion del sistema inmunitario. - Google Patents

Derivados de pirimidina, composicion farmaceutica que los comprende y el uso de esta para el tratamiento de enfermedades relacionadas con la activacion del sistema inmunitario.

Info

Publication number
AR069146A1
AR069146A1 ARP080104783A ARP080104783A AR069146A1 AR 069146 A1 AR069146 A1 AR 069146A1 AR P080104783 A ARP080104783 A AR P080104783A AR P080104783 A ARP080104783 A AR P080104783A AR 069146 A1 AR069146 A1 AR 069146A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydroxy
carboxylic acid
pyrrolidine
carboxy
Prior art date
Application number
ARP080104783A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR069146A1 publication Critical patent/AR069146A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de pirimidina, y su uso como compuestos farmacéuticamente activos. Dichos compuestos actuan, en particular, como agentes inmunomoduladores. Reivindicacion 1: Un compuesto de la formula (1) donde A representa el grupo de formulas (2) donde los asteriscos indican el enlace que se une al grupo pirimidina de la formula (1); R1 representa alcoxi C1-4, alquilamino C1-4, N-alquilo C1-4-N-alquilamino C1-3, cicloalquilamino C3-5, cicloalquilmetilamino C3-5, pirrolidina o piperidina; R2 representa alquilo C1-2 o alquilo C3-4; R3 representa hidrogeno, alquilo C1-4, o alcoxi C1-3; R4 representa hidrogeno, alquilo C1-4, o alcoxi C1-3; R5 representa 2,3-dihidroxipropilo, di-(hidroxi-alquilo C1-4)-alquilo C1-4, -CH2-(CH2)k-NHSO2R53, (CH2)nCH(OH)-CH2-NHSO2R53, -CH2-(CH2)k-NHCOR54, -(CH2)nCH(OH)-CH2-NHCOR54, -CH2-(CH2)n-CONR51R52, 1-(3-carboxi-azetidinil)-2-acetilo, 1-(2-carboxi-pirrolidinil)-2-acetilo, 1-(3-carboxi-pirrolidinil)-2-acetilo, 1-(3-carboxi-azetidinil)-3-propionilo, 1-(2-carboxi-pirrolidinil)-3-propionilo, 1-(3-carboxi-pirrolidinil)-3-propionilo, -(CH2)nCH(OH)-CH2-NR51R52, hidroxi-alcoxi C2-5, di-(hidroxi-alquilo C1-4)-alcoxi C1-4, 2,3-dihidroxi-propoxi, 2-hidroxi-3-metoxi-propoxi, -OCH2-(CH2)m-NR51R52, 2-[(ácido azetidina-3-carboxílico)-1-il]-etoxi, 2-[(ácido azetidina-3-carboxílico alquiléster C1-5)-1-il]-etoxi, 2-[(ácido pirrolidina-3-carboxílico)-1-il]-etoxi, 2-[(ácido pirrolidina-3-carboxílico alquiléster C1-5)-1-il]-etoxi, -OCH2-CH(OH)-CH2-NR51R52, 3-[(ácido azetidina-3-carboxílico)-1-iI]-2-hidroxipropoxi, 3-[(ácido azetidina-3-carboxílico alquiléster C1-5)-1-il]-2-hidroxipropoxi, 2-hidroxi-3-[(ácido pirrolidina-3-carboxílico)-1-il]-propoxi, 2-hidroxi-3-[(ácido pirrolidina-3-carboxílico alquiléster C1-5)-1-il]-propoxi, 2-hidroxi-3-[(ácido pirrolidina-2-carboxílico)-1-il]-propoxi, 2-hidroxi-3-[(ácido pirrolidina-2-carboxílico alquiléster C1-5)-1-il]-propoxi, -OCH2-(CH2)m-NHSO2R53, -OCH2-CH(OH)-CH2-NHSO2R53, -OCH2-(CH2)m-NHCOR54, o -OCH2-CH(OH)-CH2-NHCOR54; R51 representa hidrogeno, alquilo C1-3, 2-hidroxietilo, 2-hidroxi-1- hidroximetil-etilo, 2,3-dihidroxipropilo, carboximetilo, (alquilcarboxi C1-5)metilo, 2-carboxietilo, 2-(alquilcarboxi C1-5)etilo o 2-aminoetilo; R52 representa hidrogeno, metilo, o etilo; R53 representa alquilo C1-3, metilamino, etilamino, o dimetilamino; R54 representa hidroxi-alquilo C1-2 o R55R56N-alquilo C1-2; R55 y R56, de manera independiente, representan hidrogeno o metilo; k representa el numero entero 1; 2; o 3; m representa el numero entero 1 o 2; n representa 0; 1 o 2; y R6 representa hidrogeno, alquilo C1-4 o halogeno; o una sal de dicho compuesto.
ARP080104783A 2007-11-01 2008-10-31 Derivados de pirimidina, composicion farmaceutica que los comprende y el uso de esta para el tratamiento de enfermedades relacionadas con la activacion del sistema inmunitario. AR069146A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2007054437 2007-11-01

Publications (1)

Publication Number Publication Date
AR069146A1 true AR069146A1 (es) 2009-12-30

Family

ID=40577704

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104783A AR069146A1 (es) 2007-11-01 2008-10-31 Derivados de pirimidina, composicion farmaceutica que los comprende y el uso de esta para el tratamiento de enfermedades relacionadas con la activacion del sistema inmunitario.

Country Status (18)

Country Link
US (1) US8299086B2 (es)
EP (1) EP2217594B1 (es)
JP (1) JP5517944B2 (es)
KR (1) KR20100092473A (es)
CN (1) CN101970430B (es)
AR (1) AR069146A1 (es)
AU (1) AU2008320374A1 (es)
BR (1) BRPI0818804A2 (es)
CA (1) CA2700917A1 (es)
ES (1) ES2449749T3 (es)
IL (1) IL205425A0 (es)
MA (1) MA31849B1 (es)
MX (1) MX2010004576A (es)
NZ (1) NZ585775A (es)
RU (1) RU2010121969A (es)
TW (1) TW200920746A (es)
WO (1) WO2009057079A2 (es)
ZA (1) ZA201003875B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009002233A (es) * 2006-09-07 2009-03-16 Actelion Pharmaceuticals Ltd Derivados de piridin-4-il como agentes inmunomoduladores.
EP2069335B1 (en) * 2006-09-08 2012-12-26 Actelion Pharmaceuticals Ltd. Pyridin-3-yl derivatives as immunomodulating agents
US7989500B2 (en) 2006-09-15 2011-08-02 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
AU2007298593A1 (en) * 2006-09-21 2008-03-27 Actelion Pharmaceuticals Ltd Phenyl derivatives and their use as immunomodulators
ES2450750T3 (es) * 2007-03-16 2014-03-25 Actelion Pharmaceuticals Ltd. Derivados de amino-piridina como agonistas del receptor S1P1/EDG1
ES2361463T3 (es) * 2007-08-17 2011-06-17 Actelion Pharmaceuticals Ltd. Derivados de piridina como moduladores del receptor s1p1/edg1.
EP2262799B1 (en) * 2008-03-06 2012-07-04 Actelion Pharmaceuticals Ltd. Pyridine compounds
CA2714614A1 (en) * 2008-03-06 2009-09-11 Actelion Pharmaceuticals Ltd Novel pyrimidine-pyridine derivatives
NZ588439A (en) * 2008-03-07 2012-05-25 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
US8575200B2 (en) * 2008-03-07 2013-11-05 Actelion Pharmaceuticals Ltd Pyridin-2-yl derivatives as immunomodulating agents
US8389509B2 (en) 2009-01-23 2013-03-05 Bristol-Myers Squibb Company Substituted pyrazole compounds
US8354398B2 (en) 2009-01-23 2013-01-15 Bristol-Myers Squibb Company Substituted isoxazole compounds
WO2010085582A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
AR077413A1 (es) 2009-07-16 2011-08-24 Actelion Pharmaceuticals Ltd Derivados piridin-4-ilo
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
US9216972B2 (en) 2009-10-29 2015-12-22 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
US8835470B2 (en) 2010-04-23 2014-09-16 Bristol-Myers Squibb Company Mandelamide heterocyclic compounds
US8822510B2 (en) 2010-07-20 2014-09-02 Bristol-Myers Squibb Company Substituted 3-phenyl-1,2,4-Oxadiazole compounds
EP2619190B1 (en) 2010-09-24 2015-08-12 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
CN103298807A (zh) 2010-11-03 2013-09-11 百时美施贵宝公司 作为用于治疗自身免疫性疾病和血管疾病的s1p1激动剂的杂环化合物
DK2665720T3 (en) 2011-01-19 2015-07-13 Actelion Pharmaceuticals Ltd 2-methoxy-pyridin-4-yl-yl derivatives
IN2014MN01407A (es) 2011-12-30 2015-07-03 Reviva Pharmaceuticals Inc
UY35338A (es) 2013-02-21 2014-08-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen
PT2970236T (pt) 2013-03-15 2017-11-30 Idorsia Pharmaceuticals Ltd Derivados de piridin-4-ilo
AR101591A1 (es) 2014-08-20 2016-12-28 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos
HUE047646T2 (hu) 2015-05-20 2020-05-28 Idorsia Pharmaceuticals Ltd Az (S)-3-{4-[5-(2-ciklopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi} -propán-1,2-diol vegyület kristályformája
WO2017004609A1 (en) * 2015-07-02 2017-01-05 Exelixis, Inc. Thiadiazole modulators of s1p and methods of making and using
EP3507278B1 (en) 2016-09-02 2021-01-27 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
US11046646B2 (en) 2017-08-09 2021-06-29 Bristol-Myers Squibb Company Alkylphenyl compounds

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015583A1 (en) 1990-04-05 1991-10-17 The American National Red Cross A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
WO1999046277A1 (en) 1998-03-09 1999-09-16 Smithkline Beecham Corporation HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE
BR0013427A (pt) 1999-08-19 2002-07-30 Nps Pharma Inc Compostos heteropolicìclicos e seus usos como antagonistas no receptor de glutamato metabotrópico
US6559140B2 (en) * 2000-03-09 2003-05-06 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
ATE325608T1 (de) * 2001-08-13 2006-06-15 Janssen Pharmaceutica Nv 2,4,5-trisubstituted thiazolyl derivative und deren antiinflammatorische wirkung
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
JP4430941B2 (ja) 2002-01-18 2010-03-10 メルク エンド カムパニー インコーポレーテッド Ｅｄｇ受容体作動薬
US7361665B2 (en) * 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
WO2004035538A1 (en) 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
JP2006528980A (ja) * 2003-05-15 2006-12-28 メルク　エンド　カムパニー　インコーポレーテッド Ｓ１ｐ受容体作働薬としての３−（２−アミノ−１−アザシクロ）−５−アリール−１，２，４−オキサジアゾール類
EP1670463A2 (en) 2003-10-01 2006-06-21 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
US7605171B2 (en) 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
WO2005115382A1 (en) 2004-05-29 2005-12-08 7Tm Pharma A/S Crth2 receptor ligands for medicinal uses
WO2006047195A2 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
US7786132B2 (en) * 2004-12-17 2010-08-31 Amgen Inc. Aminopyrimidine compounds and methods of use
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
WO2007001973A1 (en) 2005-06-28 2007-01-04 Astrazeneca Ab New use
TWI404706B (zh) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
RU2008137553A (ru) 2006-02-21 2010-03-27 Юниверсити Оф Вирджиния Пэтент Фаундейшн (Us) Фенил-циклоалкильные соединения, содержащие гетероциклические структуры
MX2009002233A (es) 2006-09-07 2009-03-16 Actelion Pharmaceuticals Ltd Derivados de piridin-4-il como agentes inmunomoduladores.
EP2069335B1 (en) 2006-09-08 2012-12-26 Actelion Pharmaceuticals Ltd. Pyridin-3-yl derivatives as immunomodulating agents
AU2007298593A1 (en) 2006-09-21 2008-03-27 Actelion Pharmaceuticals Ltd Phenyl derivatives and their use as immunomodulators
NZ577111A (en) 2006-12-15 2012-05-25 Abbott Lab Novel oxadiazole compounds
WO2008091967A1 (en) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
ES2450750T3 (es) 2007-03-16 2014-03-25 Actelion Pharmaceuticals Ltd. Derivados de amino-piridina como agonistas del receptor S1P1/EDG1
EP2262799B1 (en) 2008-03-06 2012-07-04 Actelion Pharmaceuticals Ltd. Pyridine compounds
NZ588439A (en) 2008-03-07 2012-05-25 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
US8575200B2 (en) 2008-03-07 2013-11-05 Actelion Pharmaceuticals Ltd Pyridin-2-yl derivatives as immunomodulating agents
MY156381A (en) 2008-05-14 2016-02-15 Scripps Research Inst Novel modulators of sphingosine phosphate receptors
AR077413A1 (es) 2009-07-16 2011-08-24 Actelion Pharmaceuticals Ltd Derivados piridin-4-ilo

Also Published As

Publication number Publication date
JP2011502980A (ja) 2011-01-27
TW200920746A (en) 2009-05-16
MA31849B1 (fr) 2010-11-01
EP2217594A2 (en) 2010-08-18
MX2010004576A (es) 2010-05-17
WO2009057079A2 (en) 2009-05-07
WO2009057079A3 (en) 2009-12-03
KR20100092473A (ko) 2010-08-20
CA2700917A1 (en) 2009-05-07
AU2008320374A1 (en) 2009-05-07
EP2217594B1 (en) 2014-01-08
CN101970430A (zh) 2011-02-09
IL205425A0 (en) 2010-12-30
ZA201003875B (en) 2012-08-29
JP5517944B2 (ja) 2014-06-11
NZ585775A (en) 2011-12-22
US20100234346A1 (en) 2010-09-16
US8299086B2 (en) 2012-10-30
BRPI0818804A2 (pt) 2015-04-22
ES2449749T3 (es) 2014-03-21
CN101970430B (zh) 2013-05-08
RU2010121969A (ru) 2011-12-10

Similar Documents

Publication Publication Date Title
AR069146A1 (es) Derivados de pirimidina, composicion farmaceutica que los comprende y el uso de esta para el tratamiento de enfermedades relacionadas con la activacion del sistema inmunitario.
AR065621A1 (es) Derivados de amino-piridina, una composicion farmaceutica que los comprende y su uso como medicamento para el tratamiento de enfermedades asociadas al sistema inmune activado.
MA34604B1 (fr) Derives de la pyrazine en tant que bloqueurs de l'enac
AR062684A1 (es) Compuestos derivados de piridin-3- ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos
AR062683A1 (es) Compuestos derivados de piridin-4-ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos
AR061841A1 (es) Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
NI200700102A (es) Derivados de indol tetraciclicos como agentes antiviricos
AR061083A1 (es) Derivados de cicloalquilaminoacidos y composiciones farmaceuticas que los contienen
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
AR039672A1 (es) Dipeptido, derivado de benzotiazepina. inhibidor del transporte ileal de acidos biliares (ibat)
DOP2011000203A (es) Derivados de pirimidin indol para el tratamiento de cancer
AR049711A1 (es) Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
PA8658301A1 (es) Derivados fusionados de pirazol y metodos de tratamiento de trastornos metabolicos con estos
MA31419B1 (fr) Derives de pyridine
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
BR0317572A (pt) Benzoxazinas e seus derivados como inibidores de pi3ks
ECSP088871A (es) Derivados de triazolopirazina
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
AR067673A1 (es) Derivados de 1,3 oxazinan - 2 - ona como inhibidores ciclicos de la 11 beta -hidroxiesteroide deshidrogenasa 1. composiciones farmaceuticas.
DK2368887T3 (da) 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer
BRPI0515482A (pt) derivados heterocìclicos e seus usos como agentes terapêuticos
MA31845B1 (fr) Pipéridino-dihydrothiénopyrimidines substituées

Legal Events

Date Code Title Description
FA Abandonment or withdrawal